Peginterferon Lambda, a New Potential Therapeutic Option for the Treatment of Chronic Hepatitis B: A Phase 2B Comparison with Peginterferon Alfa in Patients with HBeAg-Positive Disease

被引：0
|
作者：
Chan, Henry Lik-Yuen [1 ]
Ahn, Sang Hoon [2 ]
Chang, Ting-Tsung [3 ]
Peng, Cheng-Yuan [4 ]
Wong, David K. [5 ]
Coffin, Carla S. [6 ]
Lim, Seng Gee [7 ]
Chen, Pei-Jer [8 ]
Janssen, Harry L. [9 ]
Marcellin, Patrick [10 ]
Serfaty, Lawrence [11 ]
Zeuzem, Stefan [12 ]
Hu, Wenhua [13 ]
Critelli, Linda [13 ]
Lopez-Talavera, Juan Carlos [13 ]
Cooney, Elizabeth L. [13 ]
机构：
[1] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China
[2] Yonsei Univ, Severance Hosp, Seoul 120749, South Korea
[3] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[4] China Med Univ Hosp, Taichung, Taiwan
[5] Toronto Western Hosp, Univ Hlth Network, Toronto, ON M5T 2S8, Canada
[6] Univ Calgary, Div Gastroenterol & Hepatol, Liver Unit, Calgary, AB, Canada
[7] Natl Univ Singapore Hosp, Singapore 117548, Singapore
[8] Natl Taiwan Univ Hosp, Taipei, Taiwan
[9] Erasmus MC, Rotterdam, Netherlands
[10] Hop Beaujon, Clichy, France
[11] Hop St Antoine, F-75571 Paris, France
[12] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany
[13] Bristol Myers Squibb Res & Dev, Wallingford, CT USA
来源：
HEPATOLOGY | 2012年 / 56卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LB14
引用
收藏
页码：1525 / 1526
页数：2
相关论文
共 50 条
  • [21] COMPARISON OF PEGINTERFERON ALFA-2A VERSUS ENTECAVIR IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B WITH MILDLY ELEVATED ALANINE AMINOTRANSFERASE LEVELS
    Chen, X. -F.
    Chen, X. -P.
    Huang, J.
    Chen, W. -L.
    Chen, R.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S328 - S329
  • [22] EXTENDING THE TREATMENT DURATION OF PEGINTERFERON ALFA-2A THERAPY TO 72 WEEKS INCREASES THE RATE OF HBeAg SEROCONVERSION IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B
    Zhu, Y. -Y.
    Dong, J.
    Chen, Y. -T.
    Chen, J.
    Jiang, J. -J.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S331 - S332
  • [23] Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon
    Wang, Gui-Qiang
    Hou, FengQin
    Xia, NingShao
    HEPATOLOGY, 2014, 60 : 1110A - 1111A
  • [24] Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon
    Hou, Feng-Qin
    Song, Liu-Wei
    Yuan, Quan
    Fang, Lin-Lin
    Ge, Sheng-Xiang
    Zhang, Jun
    Sheng, Ji-Fang
    Xie, Dong-Ying
    Shang, Jia
    Wu, Shu-Huan
    Sun, Yong-Tao
    Wei, Shao-Feng
    Wang, Mao-Rong
    Wan, Mo-Bin
    Jia, Ji-Dong
    Luo, Guang-Han
    Tang, Hong
    Li, Shu-Chen
    Niu, Jun-Qi
    Zhou, Wei-dong
    Sun, Li
    Xia, Ning-Shao
    Wang, Gui-Qiang
    THERANOSTICS, 2015, 5 (03): : 218 - 226
  • [25] RESPONSE-GUIDED PEGINTERFERON ALFA-2a (PegIFN alfa-2a) THERAPY IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B (CHB)
    Hou, J.
    Ma, H.
    Sun, J.
    Xie, Q.
    Xie, Y.
    Sun, Y.
    Wang, H.
    Shi, G.
    Wan, M.
    Niu, J.
    Ning, Q.
    Yu, Y.
    Xie, Y.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S432 - S433
  • [26] Long-term follow-up of peginterferon α treatment of HBeAg-positive chronic hepatitis B patients in phase III study of peginterferon α-2b (40kD, Y Shape) (Pegberon)
    Hou, Fengqin
    Shang, Jia
    Zhang, Mingxiang
    Pan, Chen
    Peng, Yan-zhong
    Chen, Shijun
    Zhang, Dazhi
    Zhao, Wei
    Mao, Qian-guo
    Mao, Qing
    Chen, Yongping
    Wang, Maorong
    Yin, Chibiao
    Peng, Jie
    Wang, Hao
    Meng, Qinghua
    Tan, Deming
    Sun, Li
    Wang, Guiqiang
    HEPATOLOGY, 2017, 66 : 502A - 503A
  • [27] Peginterferon alfa-2b alone or in combination with lamivudine for chronic HBeAg-positive hepatitis B: a randomized controlled trial.
    Janssen, HLA
    van Zonneveld, M
    Senturk, H
    Zeuzem, S
    Akarca, U
    Cakaloglu, Y
    Simon, K
    Kit, TSM
    Gerken, G
    de Man, RA
    Niesters, HGM
    Schalm, SW
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2005, 17 (01) : A11 - A11
  • [28] Characterization of Hepatitis B Surface Proteins in HBeAg-positive Patients with Chronic Hepatitis B (CHB) Treated With PegInterferon Alfa-2a (40KD)
    Rinker, Franziska
    Bremer, Corinna M.
    Wiegand, Steffen B.
    Bremer, Birgit
    Manns, Michael P.
    Wedemeyer, Heiner
    Yang, Lei
    Pavlovic, Vedran
    Wat, Cynthia
    Glebe, Dieter
    Kraft, Anke R.
    Cornberg, Markus
    HEPATOLOGY, 2015, 62 : 1196A - 1197A
  • [29] HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients
    Yang, Song
    Xing, Huichun
    Wang, Yuming
    Hou, Jinlin
    Luo, Duande
    Xie, Qing
    Ning, Qin
    Ren, Hong
    Ding, Huiguo
    Sheng, Jifang
    Wei, Lai
    Chen, Shijun
    Fan, Xiaoling
    Huang, Wenxiang
    Pan, Chen
    Gao, Zhiliang
    Zhang, Jiming
    Zhou, Boping
    Chen, Guofeng
    Wan, Mobin
    Tang, Hong
    Wang, Guiqiang
    Yang, Yuxiu
    Xu, Dongping
    Dong, Peiling
    Wang, Qixin
    Wang, Jue
    Bognar, Fernando A.
    Xu, Daozhen
    Cheng, Jun
    VIROLOGY JOURNAL, 2016, 13 : 1 - 9
  • [30] Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis
    Buster, Erik H. C. J.
    Hansen, Bettina E.
    Buti, Maria
    Delwaide, Jean
    Niederau, Claus
    Michielsen, Peter P.
    Flisiak, Robert
    Zondervan, Pieter E.
    Schalm, Solko W.
    Janssen, Harry L. A.
    HEPATOLOGY, 2007, 46 (02) : 388 - 394
12345